Implants have progressed from bulk materials, such as, metals, ceramics, polymers and composites to a new class of nano-engineered materials that can host cells, enhance bioactivity, serve as a substitute for the extra-cellular matrix, have controlled biodegradability and act as stem cell carriers.  The translational issues now need to consider many new aspects such as choice of ex vivo versus in vivo tissue regeneration in the functional matrix of the implant, stability of nanostructures in vivo, toxicity of nanomaterial absorption by the body etc.  This session will consider critically the translational questions associated with this new class of implants.


Thematic Keynote Overview(15 min)
Prof. Seeram Ramakrishna, Vice President, National University of Singapore, Singapore
An overview on nanostructured implants and their translational challenges will be addressed.  The value addition of nanotechnology in mimicking the extracellular matrix, providing sustained delivery of growth factors/drugs and the use of a best combination of biodegradation/strength/toughness in nanocomposites will be highlighted

Bullet Talks(5-7 min each)

  • Dr. Krishnaprasad Chennazhi, Associate Professor, Amrita Centre for Nanosciences and Molecular Medicine
    Case Study: Bone and Cardiac Tissue Engineering – Translational issues
  • Dr. Anil Patri, Scientist, Nanotechnology Characterization Laboratory, Maryland, USA
    Long term compatibility/toxicity of nanostructured implants
  • Dr. Deepthy Menon, Associate Professor, Amrita Centre for Nanosciences and Molecular Medicine
    Use of autologous materials (cells and proteins) with biomaterial carriers - Challenges
  • Dr. Y K Gupta, Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
    Regulatory questions in translation of nano-engineered implants